News

The U.S. Food and Drug Administration is reviewing an application from Vertex Pharmaceuticals seeking approval of Casgevy (exagamglogene autotemcel) for…

Building on its commitment to make insurance more accessible, especially for those affected by chronic or rare diseases, the insurer BNP Paribas Cardif is…

Sickle Cell Disease is included as an EHA 2026 disease-area keyword under non-malignant hematology, with relevant subtypes including Sickle Cell Pain Crises, Vaso-…

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses…

MITAPIVAT significantly improved haemoglobin levels and markers of haemolysis in patients with sickle cell disease (SCD) in a Phase 3 trial, with additional…

Background:Sickle cell disease (SCD) is a progressive disorder characterized by acute pain crisis (APC), organ damage, and early mortality. Despite the (few)…

New Laws Will Expand Education, Training, Access, and Coordinated Care for Virginians with Sickle CellNEWPORT NEWS, VA — Governor Abigail Spanberger today signed a…

We are a specialist centre for the diagnosis and management of adults with inherited haemoglobin disorders including sickle cell disease, thalassaemia.Who we seeWe…

IntroductionSickle cell disease (SCD) is the most common inherited blood disorder in the USA and globally, with a gradual increase in prevalence (1). SCD continues…

AbstractBackgroundSickle cell disease (SCD) is a genetic hemoglobinopathy that disproportionately affects individuals of African descent and is associated with…